acute myeloid leukemia

[Blood Cancer Discovery] This Phase Ib trial evaluated ficlatuzumab, a first-in-class anti-HGF antibody, in combination with cytarabine in acute myeloid leukemia (AML) patients. Among 17 evaluable patients, the overall response rate was 53%, all complete remissions.

[Bone Marrow Transplantation] Scientists performed a landmark study comparing long-term outcomes in acute myeloid leukemia patients alive and disease-free two years after transplantation who received grafts from either cord blood transplantation or unrelated donors.

[Clinical Cancer Research] Scientists examined the effects of a rapamycin pretreatment of epithelial cell adhesion molecule (EpCAM) chimeric antigen receptor (CAR)-T cells and assessed the in vivo antitumor efficacy of rapamycin pretreated EpCAM CAR-T cells and CD33 CAR-T cells in leukemia xenograft mouse models.

[Blood] Expression of YBX1 was significantly upregulated in myeloid leukemia cells, and deletion of YBX1 dramatically induced apoptosis and promoted differentiation coupled with reduced proliferation and impaired leukemic capacity of primary human and mouse acute myeloid leukemia cells in vitro and in vivo.

[LAVA Therapeutics, N.V.] LAVA Therapeutics N.V. announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

[Blood Advances] Untreated older acute myeloid leukemia (AML) patients were randomized to cytarabine and daunorubicin followed by cytarabine consolidation with or without G3139. Addition of G3139 to chemotherapy failed to improve outcomes of older AML patients.